

Pulse Checks

Date created: 27 August 2021

Cover sheet

Language	Generated on
English / French / Spanish	DD.MM.YYYY (prepopulated, non-editable field)

Country:	
(Disease) Component:	
Grant Name/Number:	
Principal Recipient:	
Implementation Period Start Date:	
Implementation Period End Date:	
Implementation Period Currency:	
Local Currency:	

Pulse Check Reporting Period	Start Date:	
	End Date:	
Performance Framework Reporting Period (for reference)	Start Date:	
	End Date:	

Definition of self-evaluation scale

1A - Implementation progress of HIV, TB, malaria and RSSH grant activities		
	In the next six months, programmatic indicators expected to achieve an average of:	Service delivery, financial absorption and health product procurement and supply chain management; and mitigation of key implementation risks*
On track	Above 90% of targets	AND No major challenges
Off-track with minor issues	Between 60% and 90% of targets	AND No major challenges
Off-track with major issues	Between 60% and 90% of targets	AND Major challenges
Module at risk	Below 60% of targets	AND Major challenges

*If there are challenges beyond the listed areas, please provide further detail in the comment section.

1B - Implementation progress of C19RM investments in reinforcement of national COVID-19 responses, HIV, TB and malaria mitigation, and HSS/CSS		
	Key activities in next six months expected to be:	Service delivery, financial absorption and health product procurement and supply chain management; and mitigation of key implementation risks*
On track	All implemented as planned*	AND No major challenges
Off-track with minor issues	Most implemented as planned*	AND No major challenges
Off-track with major issues	Some implemented as planned*	AND Major challenges
Intervention at risk	None implemented as planned*	AND Major challenges

*per agreed workplan

*If there are challenges beyond the listed areas, please provide further detail in the comment section.

Definition of disruption scale

1C - Cross-cutting enablers	
No/limited	<ul style="list-style-type: none"> - Stock levels: 6 month supply or more - Warehousing and distribution: More than 80% functional capacity - Lab services (HIV, TB, and / or COVID-19): More than 80% functioning as usual - LMIS reporting: More than 80% Reporting - Quality Assurance/Quality Control: Sample collection and testing not affected
Moderate	<ul style="list-style-type: none"> - Stock levels: 3-6 month supply - Warehousing and distribution: 50%-80% functional capacity - Lab services (HIV, TB, and / or COVID-19): 50%-80% functioning as usual - LMIS Reporting: 50%-80% reporting - Quality Assurance/Quality Control: 50-80% of planned samples collected and sent for testing
High	<ul style="list-style-type: none"> - Stock levels: 0-3 month supply - Warehousing and distribution: 25-50% functional capacity - Lab services (HIV, TB, and / or COVID-19): 25%-50% functioning as usual - LMIS Reporting: 25-50% reporting - Quality Assurance/Quality Control: 25-50% of planned samples collected and sent for testing
Very high	<ul style="list-style-type: none"> - Stock levels: Currently experiencing shortages - Warehousing and distribution: Less than 25% functional capacity - Lab services (HIV, TB, and / or COVID-19): Less than 25% functioning as usual - LMIS Reporting: Less than 25% reporting - Quality Assurance/ Quality Control: Less than 25% of planned samples collected and sent for testing
Don't know	
Not Applicable	

Section 1. Self-evaluation of implementation progress

Pulse Check Reporting Period:	1 Jul - 30 Sep 2021
--------------------------------------	---------------------

KEY	Drop-down menu with the following choices: On track / Off-track with minor issues / Off-track with major issues / Module at risk	Drop-down menu with the following choices: No or limited / Moderate / High / Very high / Don't know / Not Applicable
------------	--	--

A. Implementation progress of HIV, TB, malaria and resilient and sustainable systems for health grant activities

Module	Principal Recipient response	Comments
		<u>Provide an update on each module, including:</u> • implementation progress of key interventions (considering service delivery, financial absorption, health product procurement and supply chain management) • implementation bottlenecks, including disruptions as a result of COVID-19
Module 1		
Module 2		
Module 3		
Module 4		
Module 5		
Module 6		
Module 7		

B. Implementation progress of C19RM investments in reinforcement of national COVID-19 responses, HIV, TB and malaria mitigation, and HSS/CSS

Module	Interventions	Principal Recipient response	Comments
			<u>Please provide an update on each intervention, including:</u> • implementation progress (considering service delivery, financial absorption, health product procurement and supply chain management) • implementation bottlenecks, including disruptions as a result of COVID-19
COVID-19	[COVID-19 control and containment]		
	Country-level coordination and planning		
	Risk communication		
	Surveillance- Epidemiological investigation and contact tracing		
	COVID Diagnostics and testing		
	Infection prevention and control and protection of the health workforce		
	Case management, clinical operations and therapeutics		
	[Mitigation for disease programs]		
	Mitigation for HIV programs		
	Mitigation for TB programs		
	Mitigation for Malaria programs		

[Health and community systems]		
Surveillance systems		
Laboratory systems		
Health products and waste management systems		
Gender-based violence prevention and post violence care		
Respond to human rights and gender related barriers to services		
COVID-19 CSS: Community-led monitoring		
COVID-19 CSS: Community-led advocacy and research		
COVID-19 CSS: Social mobilization		
COVID-19 CSS: Community-based organizations institutional capacity building		

C. Cross-cutting enablers

	Principal Recipient response	Comments
		If "disagree" or "strongly disagree" was selected, please explain why:
My organization is collaborating systematically and effectively with the national COVID-19 response coordinating body on implementation of Global Fund-funded COVID-19 interventions	Drop-down menu with the following choices: Strongly agree / Agree / Disagree / Strongly disagree	

	Level of disruption due to COVID-19	Comments
		If "disagree" or "strongly disagree" was selected, please explain why:
National stock levels		
HIV (major ARV (Antiretroviral) regimens, HIV RTKs (Rapid Test Kits), VL (Viral Load) reagents)		
TB (Drug Susceptible (DS)-TB and Drug Resistant (DR)-TB drugs, GX cartridges)		
Malaria Artemisinin Combination Therapy (ACTs)		
COVID-19 (Ag – Rapid Diagnostic Tests (RDTs), Polymerase Chain Reaction (PCR) tests, Personal Protective Equipment (PPE))		
Warehousing and distribution (HIV, TB, malaria and / or COVID-19 commodities)		
Lab services (HIV, TB, and / or COVID-19)		
Logistics management information system reporting		
Quality assurance / Quality control of health products		

Section 2. Selected Coverage Indicators

KEY	[prepopulated / editable]	[inputs from PR]					[prepopulated, non-editable field]								
Indicator code	Indicator name	Upcoming Performance Framework target	Framework target reporting period	Cumulation type	Scope of target	Country	Apr-21	May-21	Jun-21	Apr - Jun 21	Jul-21	Aug-21	Sep-21	Jul - Sep 21	PR Comments
TCS- New	Number of adults and children newly initiated on ART														
	Target	N/A	N/A	N/A	N/A	N/A									
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
KP-1a	Number of MSM reached with HIV prevention programs- defined package of services														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
KP-3a // HTS-3a	Number of MSM that have received an HIV test during the reporting period and know their results														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
KP-3d //HTS-3d	Number of people who inject drugs that have received an HIV test during the reporting period and know their results														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
KP-3c //HTS-3c	Number of sex workers that have received an HIV test during the reporting period and know their results														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														

Indicator code	Indicator name	Upcoming Performance Framework target	Framework target reporting period	Cumulation type	Scope of target	Country	Apr-21	May-21	Jun-21	Apr - Jun 21	Jul-21	Aug-21	Sep-21	Jul - Sep 21	PR Comments
KP-3b //HTS-3b	Number of TG that have received an HIV test during the reporting period and know their results														
	Target														
	Indicator results														
	Number of reports received in the month														
KP-1d	Number of people who inject drugs reached with HIV prevention programs- defined package of services														
	Target														
	Indicator results														
	Number of reports received in the month														
KP-1c	Number of sex workers reached with HIV prevention programs- defined package of services														
	Target														
	Indicator results														
	Number of reports received in the month														
KP-1b	Number of TG reached with HIV prevention programs- defined package of services														
	Target														
	Indicator results														
	Number of reports received in the month														
PMTCT-2.1	Number of HIV+ pregnant women receiving ART for PMTCT														
	Target														
	Indicator results														
	Number of reports received in the month														
TCS-1.1	Number of adults and children currently receiving ART														
	Target														
	Indicator results														
	Number of reports received in the month														

Indicator code	Indicator name	Upcoming Performance Framework target	Framework target reporting period	Cumulation type	Scope of target	Country	Apr-21	May-21	Jun-21	Apr - Jun 21	Jul-21	Aug-21	Sep-21	Jul - Sep 21	PR Comments
YP-3 // HTS-2	Number of adolescent girls and young women (AGYW) who were tested for HIV and received their results during the reporting period														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
YP-2	Number of adolescent girls and young women (AGYW) reached with HIV prevention programs- defined package of services														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
VC-3	Number of LLINs distributed to at-risk-populations-continuous distribution														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
CM-1a	Number of suspected malaria cases that receive a parasitological test at public sector health facilities														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
CM-1b	Number of suspected malaria cases that receive a parasitological test in the community														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
CM-1c	Number of suspected malaria cases that receive a parasitological test at private sector sites														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														

Indicator code	Indicator name	Upcoming Performance Framework target	Framework target reporting period	Cumulation type	Scope of target	Country	Apr-21	May-21	Jun-21	Apr - Jun 21	Jul-21	Aug-21	Sep-21	Jul - Sep 21	PR Comments
TCP-1	Number of notified cases of all forms of TB-(i.e. bacteriologically confirmed + clinically diagnosed), includes new and relapse cases														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
MDR-TB 2	Number of TB cases with RR-TB and/or MDR-TB notified														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														
TCP 8	Number of new and relapse TB patients tested using WHO recommended rapid tests at the time of diagnosis														
	Target														
	Indicator results														
	Number of reports received in the month														
	Number of reports expected in the month														

Section 3. Financial Reporting

Cumulative data from the IP start date until:	Sep-21
--	--------

KEY	[inputs from PR]	[prepopulated, non-editable field]
------------	------------------	------------------------------------

Item No.	Description	Total Grant Funds (in grant currency)	C19RM Funds (in grant currency)	Implementation Period Funds	Comments
3	Use of funds by the Principal Recipient (breakdown of amounts):	-	-	-	
3.1	Payment for expenditures			-	
3.2	Disbursement to sub-recipients			-	
3.3	Principal Recipient open advances			-	

4	Closing balances				
4.1	Principal Recipient closing cash balance			-	
4.2	Sub-recipient open advances			-	

6	Forecast for next quarter	-	-	-	
6.1	Payment for expenditures			-	
6.2	Disbursement to sub-recipients			-	